Amrutanjan Health Care Ltd(AMRUTANJAN)

NSE: AMRUTANJANBSE: 590006

₹ 487-1.77%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 1,408 crWebsite: www.amrutanjan.com/Updated: 24 Oct 2026

About

Amrutanjan Health Care makes and sells over-the-counter pain relief products, Comfy sanitary napkins and personal care products, and rehydration beverages. Net sales were Rs 502.55 cr in FY26. Its Amrutanjan Roll On leads its category, and Comfy ranks 4th nationally in the mass pad segment.^[1][2]

Business segments

OTC Products: net sales of Rs 328.32 cr in FY26, 65.3% of revenue, with a segment result of Rs 83.44 cr.^[2][3]
Women's Hygiene & Personal Care: net sales of Rs 139.91 cr in FY26, 27.8% of revenue, with a segment loss of Rs 2.72 cr.^[2][3]
Beverages: net sales of Rs 31.56 cr in FY26 (vs Rs 36.43 cr in FY25), 6.3% of revenue, with a segment loss of Rs 6.35 cr.^[2][4][3]
Comfy made up 33% of company sales in Q1 FY27, up from 29% a year earlier.^[5]

Brands and products

Comfy, the women's hygiene brand launched in 2013, is 4th nationally in the mass pad segment (FY26).^[2]
The XL variant was 37% of Comfy sales in FY26, up from 31% a year earlier.^[6]
The rehydration brands are Amrutanjan Electro+ ORS and Amrutanjan Enerlyte. Electro+ gross sales fell 14% in FY26.^[2][6]
The rubefacients category was valued at Rs 8,229 crore in FY26, and the company outperformed it on volume growth.^[2]
Launches in Q4 FY26: razors for women and men, an antiseptic plaster, Ortho Pain Oil and a nasal spray.^[6]
Razors and Plastry made up 4% of sales in Q1 FY27. Razors earned Rs 3 cr and were in 70k outlets; Plastry earned Rs 1.12 cr.^[5]

Manufacturing

OTC factories are at Alathur (Tamil Nadu) and Uppal (Hyderabad); the beverage plant is at Aranvoyal Village, Tiruvallur (FY26).^[2]
A cGMP allopathic facility makes OTC monograph topical products that are registered with the USFDA and exported to the USA.^[2]
The fifth plant, a Rs 150 cr greenfield sanitary napkin facility in Telangana with two high-speed automated lines from Japan, was commissioned; the FY26 annual report gives its capacity as 700 mn napkins.^[5][2]

Key operating numbers

Pain category volume fell 3.4% in Q1 FY27 (IQVIA), against 6.6% growth in Q1 FY26. Pain gross sales fell 9% in the quarter.^[5]
Pain category gross sales grew 10% in FY26, and body ache grew 16%.^[6]
Advertising and promotion spend was Rs 3.03 cr in Q1 FY27, vs Rs 1.59 cr a year earlier. FY26 spend was Rs 39 cr, vs Rs 33.92 cr in FY25.^[5][6]

Distribution and reach

The company had 3,994 distributors and sub-distributors in FY26.^[2]
In Q1 FY27, outlet coverage rose 17%, lines sold 20%, the stockist network 7% and productive calls 9%.^[5]
44K new chemists were added in FY26 toward a goal of 100K by September FY27. A rural van programme runs in 9 states.^[6]
E-commerce revenue was Rs 14.12 crore in FY26, up 48.8%.^[2]
Amrutanjan Relief was launched in the US through Amazon US in FY26, and World of Amrutanjan stores operate in Delhi, Ahmedabad and Chennai.^[2]

Plans

Management expects about Rs 15 cr from razors and about Rs 10 cr from Plastry in FY27, and aims for Comfy to turn profitable in FY27.^[5]
The congestion brand Relief is to be relaunched in FY27.^[6][2]
Process digitisation is to rise from 68% to about 85% in FY27 through DMS and SAP TM.^[6]

Company facts

The company had 661 employees in FY26 and has no subsidiaries, associates or joint ventures.^[2]
ESOP 2 was withdrawn in FY26 because sales targets were not met and the share price fell.^[2]

Market Cap

₹1,408 Cr

High / Low

₹759 / 477

Stock P/E

26.1

Price / Book

3.8

Book Value

₹128

EPS

₹20.0

No. of Shares

2.89 Cr

ROCE

24.9%

ROE

16.6%

OPM

16.7%

Debt / Equity

0.00

Sales

₹503 Cr

Net Profit

₹58 Cr

Promoter holding

46.5%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials

Amrutanjan Health Care Ltd(AMRUTANJAN)

About

Business segments

Brands and products

Manufacturing

Key operating numbers

Distribution and reach

Plans

Company facts

Signal history

The analysis Screener can't give you

AI Deep Dive

Verdict

Company data

Product Segments

Corporate Actions